Premium
SCHEDULE‐INTENSIFIED M‐VAC CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (rhG‐CSF)
Author(s) -
Noguchi Sumio,
Kubota Yoshinobu,
Shuin Taro,
Hosaka Masahiko,
Miura Takeshi,
Kondoh Iichirou
Publication year - 1994
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1994.tb00023.x
Subject(s) - medicine , granulocyte colony stimulating factor , urothelial cancer , recombinant dna , chemotherapy , schedule , granulocyte , cancer research , oncology , urology , cancer , bladder cancer , gene , biochemistry , chemistry , computer science , operating system
M‐VAC (Methotrexate, vinblastine, adriamycin and cisplatin) combination systemic chemotherapy is useful for treating invasive or metastatic transitional cell carcinoma. Granulocytopenia is the major dose‐limiting factor of this chemotherapy and it takes 4 weeks or more to complete a single course of M‐VAC. We have tried to shorten the period of M‐VAC chemotherapy from 4 to 3 weeks by using rhG‐CSF. With this modified M‐VAC regimen, the number of days on which the absolute neutrophil count was less than 10007mm 3 was significantly reduced and the period to reach the neutropenia nadir was shortened. No severe side‐effects were observed. In all patients treated with 2 courses of this modified M‐VAC short regimen, the period of hospitalization could be reduced by 2 weeks. We emphasize the possibility of shortening the M‐VAC regimen.